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amino mitoxantrone analogue and DNA: a pathway to major-minor groove cross-
linked adducts 
Abstract 
The major covalent adduct formed between a 13C-labelled formaldehyde activated bis-amino 
mitoxantrone analogue (WEHI-150) and the hexanucleotide d(CG5MeCGCG)2 has been isolated by HPLC 
chromatography and the structure determined by NMR spectroscopy. The results indicate that WEHI-150 
forms one covalent bond through a primary amine to the N-2 of the G2 residue, with the polycyclic ring 
structure intercalated at the 5MeC3pG4/G10p
5MeC9 site. Furthermore, the WEHI-150 aromatic ring system 
is oriented approximately parallel to the long axis of the base pairs, with one aliphatic side-chain in the 
major groove and the other side-chain in the minor groove. This study indicates that mitoxantrone 
derivatives like WEHI-150 should be capable of forming major-minor groove cross-linked adducts that will 
likely produce considerably different intracellular biological properties compared to known anthracycline 
and anthracenedione anticancer drugs. 
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Abstract 
 
The major covalent adduct formed between a 13C-labelled formaldehyde activated bis-amino 
mitoxantrone analogue (WEHI-150) and the hexanucleotide d(CG5MeCGCG)2 has been isolated by 
HPLC chromatography and the structure determined by NMR spectroscopy. The results indicate that 
WEHI-150 forms one covalent bond through a primary amine to the N-2 of the G2 residue, with the 
polycyclic ring structure intercalated at the 5MeC3pG4/G10p
5MeC9 site. Furthermore, the WEHI-150 
aromatic ring system is oriented approximately parallel to the long axis of the base pairs, with one 
aliphatic side-chain in the major groove and the other side-chain in the minor groove. This study 
indicates that mitoxantrone derivatives like WEHI-150 should be capable of forming major–minor 
groove cross-linked adducts that will likely produce considerably different intracellular biological 




The dose-limiting toxicities of the anthracycline class of anticancer drugs (e.g. doxorubicin) have 
promoted the search for new anthracenedione derivatives with comparable cytotoxicity but lower 
cardiotoxicity. Mitoxantrone (see Fig. 1) is a synthetic second-generation anthracycline derivative that 
is clinically used for the treatment of a variety of cancers.1–3 It exhibits significantly lower 
cardiotoxicity than the anthracyclines but maintains potent anticancer activity.4,5 Mitoxantrone and 
related derivatives can bind DNA by intercalation and induce a cytotoxic effect through the 
impairment of topoisomerase II.6,7 More recently, it has been demonstrated that mitoxantrone can also 
form a covalent adduct at the N-2 amino group of a guanine nucleotide in DNA, after activation of a 
side-chain amine by formaldehyde, that potentially leads to apoptosis independently of topoisomerase 




Fig. 1 Structure of mitoxantrone and WEHI-150. 
The atom numbering of WEHI-150 is given.  
 
WEHI-150 is a bis-amino mitoxantrone analogue (see Fig. 1) that contains two potentially reactive 
amine groups in each side-chain. As a consequence WEHI-150 can more rapidly and more 
extensively form covalent adducts with DNA than mitoxantrone.10 In order to further develop the 
anthracenedione class of anticancer drugs it is important to determine the structure of a mitoxantrone– 
or mitoxantrone derivative–DNA adduct. Previous studies have demonstrated that WEHI-150 
preferentially intercalates and then forms covalent adducts with DNA at CpG sites.10 In addition, 
WEHI-150 forms significantly more covalent adducts when the cytosine at the CpG site is methylated 
at the C-5 position (5MeCpG).10 Consequently, we sought to isolate by HPLC the major covalent 
adduct formed between WEHI-150 and the hexanucleotide d(CG5MeCGCG)2 and then examine its 
structure by NMR spectroscopy. 
 
Materials and methods 
The oligonucleotide d(CG5MeCGCG)2 was obtained from GeneWorks, South Australia, and WEHI-
150 was synthesised as previously described.11 The covalent adduct was produced by incubating the 
oligonucleotide d(CG5MeCGCG)2 (20 μM) with WEHI-150 (40 μM) and formaldehyde (
13C, 2 mM) in 
100 mM ammonium acetate pH 6.8 at 37 °C for 10 hours. The un-reacted (including the reversibly 
bound) WEHI-150 was removed by phenol/chloroform extraction and the DNA precipitated by the 
addition of absolute ethanol. The WEHI-150–DNA adducts, a blue precipitate, were dissolved in 100 
mM ammonium acetate pH 6.8 prior to injection into the HPLC. HPLC separation was repeatedly 
performed on a Shimadzu prominence (UFLC) with Waters Delta pak C4, 3.9 × 150 mm, 5 micron, 
analytical column using a 100 mM ammonium acetate (pH 6.8) and acetonitrile gradient as the mobile 
phase. The major covalent adduct (collected at 90% ammonium acetate and 10% acetonitrile) from 
each reaction mixture was collected manually into a vessel containing chilled phosphate buffer (10 
mM, pH 7.0 containing 20 mM NaCl and 1 mM EDTA) to avoid adduct degradation. The isolated 
covalent adduct contained a small amount (≈15%) of the free hexanucleotide. The free hexanucleotide 
did not interact with the WEHI-150–hexanucleotide adduct in the subsequent NMR experiments.  
The molecular modelling investigations were carried out using HyperChem Release 7.5 software 
as previously described.10 Duplex B-DNA was generated from the nucleic acid database. Energy 
restraints were added to maintain the H-bonds as expected in duplex DNA during the optimisation 
procedures. The duplex DNA was optimised in vacuo by applying the Amber 99 force field and a 
Polak-Ribiere conjugant algorithm with a 5 × 10−5 kcal (Å mol)−1 convergence criterion. WEHI-150 
atom charges were defined using the AM1 semi-empirical method. The models were constructed 
based on the intermolecular NOEs observed between the drug and oligonucleotide. Energy restraints 
(force constant 7 kcal Å−2) were then applied to maintain a maximum distance of 3.5 Å between any 
drug and oligonucleotide protons that gave strong NOEs in the NOESY spectra. The drug-
oligonucleotide complex was then energy minimised using the AMBER 99 molecular mechanics 
optimisation process. The distance restraints were then removed and the structure re-optimised to 
obtain a local energy minimum. 
Results and discussion 
In preliminary experiments, the reactions of WEHI-150 with guanosine, guanosine monophosphate 
(GMP) and the oligonucleotide d(CG5MeCGCG)2, in the presence of formaldehyde, were monitored by 
HPLC. The results demonstrated that significant amounts of the covalent adduct were formed with 
d(CG5MeCGCG)2 in 4 hours, whereas with the single nucleotides no covalent adduct formation was 
observed in 24 hours. These results demonstrate the need for the initial reversible association with 
DNA in order to form the WEHI-150–DNA covalent adduct.  
Experiments were carried out to determine the stability of the major covalent adduct as a function 
of pH (after a 12-hour incubation) and incubation time at pH 7.0. The percentage of remaining intact 
covalent adduct was determined by HPLC with UV detection. The results showed that the adduct was 
more stable at basic pH compared to acidic conditions. No adduct was observed after a 12-hour 
incubation at pH 3.1 at 37 °C, whereas approximately 75% of the adduct remained intact at pH 7, 
indicating the WEHI-150–d(CG5MeCGCG)2 adduct was moderately stable at neutral pH. The covalent 
adduct was incubated at 37 °C in 10 mM phosphate buffer at pH 7.0 and the amount of remaining 
intact covalent adduct monitored by HPLC at different time intervals. Approximately 50% of the 
covalent adduct was observed after 33 hours incubation at 37 °C, indicating that the covalent adduct 
was highly stable compared to the parent drug mitoxantrone.12 It was also noted that WEHI-150–
d(CG5MeCGCG)2 adduct appeared to be degraded to free DNA. 
Mass spectrometry was used to identify the number of WEHI-150 molecules and the number of 
CH2 covalent links formed in the major WEHI-150–d(CG
5MeCGCG)2 covalent adduct that was 
isolated by HPLC. Ionisation by electrospray produces a range of charge states for oligonucleotides as 
a function of the sequence and length. Under the conditions used the 3− charge state was observed as 
the most abundant species in the spectrum for the WEHI-150–d(CG5MeCGCG)2 covalent adduct. The 
obtained m/z values for the covalent adduct are in agreement with the calculated m/z values for the 




Fig. 2 Negative ion electrospray mass spectrum of the major 
WEHI-150–d(CG5MeCGCG)2 covalent adduct focussed on 
the 3− state mass range, showing one CH2 link between 
WEHI-150 and the oligonucleotide duplex d(CG5MeCGCG)2. 
The obtained m/z values are given in brackets which are in 
agreement with calculated m/z values. 
 
The major WEHI-150–d(CG5MeCGCG)2 adduct was then examined by 
1H NMR spectroscopy. A 
HSQC experiment was performed to confirm the results observed by mass spectrometry that indicated 
the covalent adduct contained only one CH2 link between the drug and the oligonucleotide. The 
results showed one 13C signal at 58.8 ppm with two 1H signals for the non-equivalent methylene 
protons at 3.44 and 4.04 ppm (see ESI Fig. S1†), consistent with formation of a single CH2 link in the 
covalent adduct. The aromatic region of the 1H NMR spectrum of the covalent adduct is shown in Fig. 
3, with the full width spectra given in Fig. S2 in the ESI.† The observation of multiple sharp signals in 
the spectrum indicates the loss of the oligonucleotide duplex symmetry upon covalent adduct 
formation with WEHI-150. The oligonucleotide base residue numbers are given from 1 to 12 for the 
two DNA strands, S-1 and S-2 (see Fig. 3). Upon covalent adduct formation, the resonances from the 
aromatic protons of WEHI-150 shifted significantly upfield (see ESI Table S1†), compared to the free 




Fig. 3 Oligonucleotide residue numbering is 
shown (top). The aromatic region of the 1H NMR 
spectrum of the free oligonucleotide 
d(C1G2
5MeC3G4C5G6)2 (A) and the WEHI-150 
covalent adduct with d(C1G2
5MeC3G4C5G6)2 (B) in 
pH 7.0 phosphate buffer in D2O at 10 °C. H6 and 
H8 protons of the free hexanucleotide are shown 
in A. The WEHI-150 H2, H3 protons and the H6 
protons of the 5-methylated cytosines are 
indicated in B for the covalent adduct. 
 
 
OESY and DQFCOSY spectra were recorded to obtain a detailed picture of the WEHI-150 
covalent adduct with d(CG5MeCGCG)2. The resonances at 6.82 and 6.50 ppm were assigned to the H2 
and H3 protons of WEHI-150, respectively, as these protons showed coupling in DQFCOSY spectra 
with no connectivity to the aliphatic protons of WEHI-150 in NOESY spectra. The resonance at 6.09 
ppm was assigned to the WEHI-150 H6/H7 protons as these protons showed strong NOEs with the 
aliphatic resonances of WEHI-150. A range of intermolecular NOEs were observed between the 
WEHI-150 and the d(CG5MeCGCG)2 protons. In particular, NOEs were observed from the WEHI-150 
H2 and H3 protons to the methyl and the H2′′ protons of the 5MeC3 of S-1 (see Fig. 4). In addition 
weak NOEs were observed from the WEHI-150 H3 proton to the H6 and H8 protons of the 5MeC3 and 
G4 residues of S-1. These intermolecular NOEs strongly suggest that WEHI-150 binds preferentially 
at the 5MeC3pG4/G10p
5MeC9 site. In addition, the loss of the sequential NOEs from 
5MeC3 to G4 confirms 




Fig. 4 Expansion of a NOESY spectrum of the WEHI-150 covalent adduct 
with d(C1G2
5MeC3G4C5G6)2 in pH 7.0 phosphate buffer in D2O at 10 °C. The 
expansion shows NOE connectivities from the WEHI-150 H2, H3 and H6/7 
protons to the oligonucleotide methyl and sugar H2′′ protons of the 5-methyl 
cytosines, and from the WEHI-150 aliphatic protons to the 5MeC9H1′ proton. In 
the empty box region cross peaks would be expected if the WEHI-150 H2 and 
H3 protons are close to the methyl protons of the 5-methyl cytosine (5MeC9 S-
2). Absence of these cross peaks suggests that the WEHI-150 chromophore is 
oriented parallel to the DNA base pair. 
 
A relatively strong NOE was observed between the H2 of WEHI-150 and the oligonucleotide 
5MeC3 methyl protons, whereas, only a weak NOE was observed between the H3 and the 
5MeC3 methyl 
protons. In contrast, a strong NOE was noted between the H3 and the 5MeC3H2′′ protons and a weak 
NOE between the H2 and 5MeC3H2′′. These observations suggest the H3 proton is located under the 
5MeC3 base whereas the H2 proton is positioned more towards the major groove of the oligonucleotide. 
Of further note, NOEs of medium intensity were observed from the WEHI-150 H6/H7 protons to the 
oligonucleotide 5MeC9H6 and 
5MeC9CH3 protons. Observation of NOEs from the WEHI-150 H2, H3 
and H6/H7 protons to only major groove oligonucleotide protons suggests that the long axis of the 
polycyclic ring system of WEHI-150 is positioned more parallel, than perpendicular, to the base pairs 
at the intercalation site. Consistent with this proposition was the observation of NOEs from the 
aliphatic side-chain protons to both major (5MeC9H6 and 
5MeC9CH3) and minor groove (G2H1′ and 
C9H1′) protons (see Fig. 4 and ESI Fig. S3†). 
NOESY experiments were carried out in 90% H2O/10% D2O to assign the imino resonances of the 
free and WEHI-150-bound covalent adduct (see ESI Table S2†). While significant upfield shifts were 
observed for the G2, G4, G8 and G10 imino resonances, the G2 imino exhibited the greatest shift. An 
NOE was observed between the G2 imino proton and a NH proton at 10.00 ppm. The large shifts 
noted for the G2 imino and amino protons suggests that WEHI-150 forms a covalent adduct with the 
N-2 of G2. Consistent with this conclusion is the assignment of the NH proton of a N-2 alkylated 
guanine at 9.57 ppm by Moore et al. in their study of the covalent reaction of ecteinascidin 743 with 
an oligonucleotide.13 As it would not be possible for WEHI-150 to reach the N-2 of G2 through the 
formation of a covalent link with one of the secondary amines while intercalating at the 5MeCpG site, it 
can be further concluded that the covalent adduct was formed through the reaction of a primary side-
chain amine group. 
Taken together the MS and NMR results indicate that WEHI-150 forms one covalent bond through 
a primary amine to the N-2 of the G2 residue, with the polycyclic ring structure intercalated at the 
5MeC3pG4/G10p
5MeC9 site. Furthermore, the WEHI-150 aromatic ring system is oriented approximately 
parallel to the long axis of the base pairs, with one aliphatic side-chain in the major groove and the 
other side-chain in the minor groove. Although the NMR data was not sufficient to allow the 
determination of the structure of the covalent adduct by restrained molecular dynamics, simple energy 
minimised (to remove steric clashes) models could be constructed that were consistent with the NMR 
data. The model shown in Fig. 5 indicates that the proposed “threaded” structure (aliphatic side-chains 
in major and minor grooves) is feasible. Models were constructed keeping both aliphatic side chains 
in the minor groove as observed with the reversible binding;10 however, the resultant models were not 
consistent with the observed NOEs and thus the models were discounted (e.g. see ESI Fig. S4†). A 
number of compounds, both organic (e.g. nogalamycin) and transition metal complexes (e.g. dinuclear 




Fig. 5 Energy minimized HyperChem model of 
the WEHI-150 covalent adduct with 
d(CG5MeCGCG)2. The DNA is shown in cyan, the 
WEHI-150 in yellow, the WEHI-150 H2, H3 and 
H6/H7 protons in green and the CH2 derived from 
formaldehyde in red. The model shows one side-
chain located in the major groove and other side-
chain in the minor groove. 
 
 
The structures of formaldehyde-cross-linked adducts of the anthracyclines daunorubicin and 
doxorubicin with oligonucleotides have been previously reported;18,19 however, this study reports for 
the first time (to our knowledge) the structure of a mitoxantrone analogue–DNA covalent adduct. 
Although the anthracycline–DNA adducts contain a CH2 link to the N-2 of a guanine residue, the 
polycyclic ring system is positioned perpendicular to the base pairs at the intercalation site in a similar 
manner to that found for the reversibly bound drugs.20 Furthermore, the entire covalently bound 
anthracycline drug resides in the DNA minor groove. 
The results of this study indicate that WEHI-150 remains intercalated at the 5MeCpG site and forms 
a covalent link through a methylene group to the N2-amino group of a guanine residue adjacent to the 
intercalation site. However, and interestingly, the NMR results were only consistent with a threaded 
structure where the WEHI-150 has one side-chain in the major groove and the other in the minor 
groove. Furthermore, the results clearly demonstrated that the primary amine of WEHI-150 was 
significantly more reactive than the secondary amine. This suggests a mitoxantrone derivative with an 
amine in each side-chain, with extended methylene chains, might be the optimal anthracenedione. 
Furthermore, the addition of asymmetric side-chains may yield an anthracenedione capable of 
facilitating dual covalent bond formation, and thus higher stability as well as posing a greater 
challenge for cellular DNA repair responses. In particular, our work raises the likelihood that the 
threaded structure is capable of covalent linkages in both the DNA minor and major grooves. In a 
previous study,10 it was found that one WEHI-150 could form adducts with one, two and even three 
CH2 covalent links to an oligonucleotide. Consequently, it is likely that one of the amine groups 
located in the major groove by the threaded structure can form a covalent link, after activation by 
formaldehyde, with a nucleophilic nitrogen (e.g. the N7 of a guanine residue) in the major groove. 
Additionally, in order to potentially increase the proportion of such a major–minor groove covalent 
cross-linking drug, novel mitoxantrone analogues can now be envisioned that contain an electrophilic 
carbon on one side-chain (through replacement of the terminal amine with a CH2-Cl) that would more 
readily react with nucleophilic groups in the DNA major groove. 
In conclusion, the threaded adduct structure we have observed for the mitoxantrone analogue 
WEHI-150, and the proposed major–minor groove cross-linked adduct (a new type of drug-DNA 
binding motif) will likely produce considerably different intracellular biological properties compared 
to anthracycline–DNA covalent adducts. For example, the stabilised threaded structure is more likely 
to inhibit transcription due to interfering with the binding of transcription factors in the DNA major 
groove. 
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